فهرست مطالب soudabeh shahid sales

Colorectal cancer is one of the most common gastrointestinal cancers, and it is the third and fourth most common cancer among Iranian men and women, respectively. Patients suffering from cancer have different information needs, and one of the most important and reliable sources of information for them is their physicians. Therefore, this study aimed to assess the sources and information needs of patients suffering from colorectal cancer and physicians' viewpoints regarding this issue.

This cross-sectional questionnaire survey-based study was conducted from May to December 2017. All patients diagnosed with colorectal cancer and physicians in oncology outpatient clinics at a specialized cancer hospital and a radiotherapy oncology center in Mashhad, Iran were invited to participate in the study using the census technique. The patient questionnaire was about patients' attitudes toward the consultant's information and disease, information leaflets, the treatments and complications and information sources for the disease. The physician questionnaire was about the information the physician would give to the patients.

The mean ages of the patients and physicians participating in this study were 50.72±16.15 and 40.03±11.08 years, respectively. Most of the cases (44.8%) wanted to know everything about their illness as much as possible, while 45.5% of the patients needed the information. The majority (85.9%) of the participants were willing to know about all possible therapies regarding their illness, while 63.3% of the physicians provided treatment options that were suitable for the patient in their view, and only 33.3% of the physicians told the patients all possible treatment options.

Information regarding the illness, diagnosis, and treatment is one of the essential needs for patients suffering from colorectal cancer. It seems that it is necessary to have a good and organized plan to provide the patients suffering from colorectal cancer with the required information and increase their health information literacy as one of their undeniable rights.

Cancer diagnosis is a threatening and traumatic experience. Confusion caused by distressing thoughts about cancer can lead to additional suffering and, along with avoidance, can be a key factor in maintenance of traumatic reactions. The current research aimed at comparing the effectiveness of Unified Protocol (UP) of transdiagnostic intervention and mindfulness based schema therapy (MBST) on posttraumatic avoidance (PA) and chronic illness-related cognitive fusion (CICF) in patients with breast cancer (BC).

A semi-experimental study with pretest-posttest design and a follow-up period of 45 days was performed. Statistical population included all female patients with BC in Mashhad, Iran 2018-2021. Cognitive Fusion Questionnaire-Chronic Illness (CFQ-CI) and Posttraumatic Avoidance Scale (PAS) were administered. Forty one patients were selected using purposive sampling and were randomly divided into two experimental groups and a control group. UP of transdiagnostic intervention and MBST were applied in intervention groups for 10 weekly sessions. The control group attended two educational sessions. Data analysis was done using multivariate covariance analysis and Bonferroni post hoc test.

The mean scores for CICF and PA were significantly different between the intervention groups and the control group at post-test and follow-up (P<0.001). Findings showed no significant difference between the effectiveness of UP and MBST at post-test and follow-up (P>0.05).

MBST and UP are suggested to be applied in patients with BC to reduce their psychological problems.

Breast cancer is the most commonly diagnosed cancer in women which can cause spiritual distress in them. This study aims to assess the effects of mindfulness-based schema therapy (MBST) and transdiagnostic intervention on spiritual distress of women with breast cancer.

This is a quasi-experimental study (Clinical trial) with a pre-test/post-test/ follow-up design using a control group. Participants were 41 women with breast cancer referred to Omid and Imam Reza hospitals in Mashhad, Iran during 2017-2020, who were selected using a convenience sampling method and randomly assigned into two experimental groups and one control group. For both experimental groups, the intervention was performed at ten weekly sessions. The used instrument was the Spiritual Distress Scale of Ku et al. Data were analyzed using repeated measures analysis of variance and Bonferroni post hoc test in SPSS software, version 25 software.

There was a significant difference in the mean scores of spiritual distress in the experimental groups compared to the control group in the post-test and follow-up phases (P<0.001). There was no significant difference between the effectiveness of transdiagnostic intervention and MBST in the post-test and follow-up phases (P>0.05).

Both transdiagnostic intervention and MBST can reduce the spiritual distress of women with breast cancer.

Diagnosis of cancer is very distressing and causes a lack of control and insecurity in the suffering person. Resilience and self-efficacy are two essential support factors that can help these people; therefore, the present study aimed to compare the effectiveness of mindfulness-based schema therapy and transdiagnostic intervention in women with breast cancer on cancer self-efficacy and resilience along with a follow-up period.

The research method was quasi-experimental with a pretest-posttest design and a follow-up period of 45 days. The statistical population included female patients with breast cancer in 2019-2022 referred to Omid and Imam Reza hospitals in Mashhad, Iran. The instruments were the Cancer Self-efficacy Questionnaire of Champion et al. (2013) and the Cancer Resilience Questionnaire of Sonaga and Futavatari (2018). In total, 41 subjects were purposefully selected from the population and randomly assigned to the experimental and control groups. For the two experimental groups, the intervention was performed for 10 weekly sessions. Data analysis was performed using the repeated measures analysis of variance (ANOVA) test and Bonferroni post hoc test using the SPSS statistical software (version 25) at the significance level of 0.05.

There was a significant difference between the mean scores of the first and second experimental groups and the control group in the post-test and follow-up concerning resilience (P<0.007) and self-efficacy (P<0.01). On the other hand, there was no significant difference between transdiagnostic effectiveness and mindfulness-based schema therapy in the post-test and follow-up (P>0.05).

Based on the present findings, it is suggested to reduce the psychological problems of women with breast cancer through mindfulness-based schema therapy and transdiagnostic treatment

Prediction of response to neoadjuvant treatment is an important part of treatment of patients with breast cancer. This study aimed to assess changes in serum levels of Cytokeratin 18 during neoadjuvant chemotherapy in patients with locally advanced breast cancer and its association with neoadjuvant treatments.

This research was performed on newly diagnosed breast cancer patients referred to Omid Radiotherapy Center and radiotherapy and oncology departments of Emam Reza and Ghaem hospitals, in Mashhad, Iran. Serum levels of M30 and M65 fragments of Cytokeratin 18 were measured before and 24 hours after the first course of neoadjuvant chemotherapy. Changes in serum levels of Cytokeratin 18 and its fragments and their correlation with pathologic response were analyzed.

Pre- and post-chemotherapy levels of M30 were respectively 223.9±18.94 and 250.7±23.92 U/L (P=0.24). For M65, these levels were respectively 301.5±313.9 and 330.2±352.2 U/L (P=0.1). Changes in M30 level during chemotherapy in patients with and without pathologic complete response were -20±92.69 and 43.1±106.5, respectively (P=0.1). For M65, these changes were respectively -247±55 and 76±240 (P=0.1). Baseline levels of M30 and M65 had no relation with menopausal status, tumor grade, hormone receptor status, Ki67 expression, molecular subtype, and stage.

Our findings showed statistically insignificant changes in the level of Caspase-cleaved- (M30) and uncleaved- (M65) cytokeratin 18 fragments (apoptotic and necrotic indicators, respectively) during neoadjuvant chemotherapy in patients with breast cancer. There was no notable relationship between tumor-related factors and either baseline levels or serum changes of CK18 fragments. Also, there was no correlation between M30/M65 level and pathologic response to neoadjuvant chemotherapy.

  Breast cancer is one of the most common and worrisome diseases among women all over the world which becomes more difficult with localized relapses and metastases in this disease and the chance of survival is reduced. therefore the effect of various factors on the incidence of metastases can have an important role in the treatment and prevention of disease progression. In this study, 1959 women with breast cancer who referred to Omid Hospital in Mashhad from 2001 to 2011 were selected and evaluated. To analyze the data, after the imputation of missing data, the method of penalized profile likelihood was used and data analysis was done in the software R. The results of the analysis showed that family background, clinical stage, Her2 protein, and T (tumor size) variables had a significant effect on the incidence of metastasis in breast cancer patients. According to the results, the stage code and her2 variables, tumor size and family history in all conditions of analysis had a significant effect on the incidence of metastasis in patients with breast.

Colorectal cancer (CRC) is the third common cancer worldwide and its death rate is increasing in Iran. The present study is conducted with the purpose of determining related factors to CRC patients’ survival using Cox regression model. In a historical cohort, we examined 404 subjects who were diagnosed with CRC and referred to Omid Hospital in Mashhad from 2006 through 2011. First demographic and clinical information of patients were gathered and then were followed until September 2016. In this paper, Cox regression was utilized to investigate related factors to CRC patients’ survival. For statistical analysis SPSS software was applied and significant level was 0.05. In this research, 217 men (53.7%) and 187 women (46.3%) were studied. The mean±sd of subjects’ age was 56.4±14.7 years and 3- year, 5-year and 7-year survival rates of patients were 0.60, 0.50 and 0.48 respectively. In this study, the median (95% confidence interval) of survival times was calculated 5.48 (3.07, 7.90). According to Cox regression model, BMI (p=0.024), first treatment (p=0.019), stage (p

Globally, breast cancer is the most common malignancy among females. Prohibition (PHB)-I, a homologous protein, was initially introduced as a suppressor gene for amplification process. Further, the protein has a key role in the cell cycle and is capable of inhibiting DNA transcription in many cell types. Therefore, its possible role in different types of human malignancies is of interest.
The current study aimed at examining the relationship between the tissue distribution of PHB-I and prognostic factors of breast cancer.
Paraffin-embedded tissue specimens of 33 patients diagnosed with breast cancer at Omid teaching Hospital, Mashhad, Iran were studied and a commercial monoclonal antibody was used to perform immunohistochemistry (IHC). The relationship between PHB-I tissue expression with age, disease stage, tumor grade and size, as well as hormone receptor status including estrogen (ER) and progesterone (PR) receptors, and Her-2 receptor were evaluated.
The Immunohistochemical analysis showed a relative increase in PHB-I tissue expression along with higher tumor grade (P=0.057). In addition, higher expression of ER and PR were observed (P=0.027 and 0.009, respectively). The age of patients and other prognostic factors including Her-2 receptor status and disease stage did not statistically correlate with PHB-I expression.
An increased expression of PHB-I was observed in the breast cancer tumors of the current study patients compared with the anatomically healthy margin. Its coloration with some prognostic factors such as disease grade and expression of ER and PR might indicate the PHB-I potential application for diagnostic and patient management purposes.

Breast cancer is the most common cancer in women and can have several profound effects on women’s life. Estrogen and androgens reduction cause sexual problems. Reduction of hormones produce problems such as vaginal dryness, vaginal and vulvar tissue thinning, loss of elasticity of the vagina, hot flashes and other problems. Depression in these patients is also a factor in reducing sexuality. Disruption at any sexual stage can cause sexual problems. In this article; we compare sexual dysfunction in patients with breast cancer and healthy people.
According to the women’s case-control study with simple un-randomized sampling method a total of 245 patients with breast cancer in Ghaem and Emam Reza and Omid hospital from july 2011 to july 2013 entered the study. All patients were on follow-up after therapy, and had a therapy portfolio. In order to achieve better results, questionnaires were distributed among 126 healthy subjects that matched our patient group in terms of age and other factors and were used as the control group. Female sexual function index (FSFI) questionnaire was filled out by an independent interviewer and all medical, personal and social ethics were applied. The data was then gathered and the score were analyzed with statistical tests.
The study was performed on patients 20 to 50 years, mainly in patients aged 35 to 45 years (51.8%). The average age was 41.44±5.87 years. In our study, the most dysfunction was in sexual desire (57.6%), vaginal moisture (53.1%), sexual excitement (48.2%), orgasm (44.1%), and dyspareunia (52.2%) in breast cancer patients. There was significant difference between two group (P Sexual dysfunction is common in breast cancer patients compared to healthy women. Dysfunction in orgasm, dyspareunia, reducing vaginal moisture and sexual desire were common in the breast cancer patient. The results of this study should be used to inform patients and physician about sexual problems.

Breast cancer is the most common type of cancer in women. 35% of breast cancer is reported in women older than 70 years. This study was performed with aim to evaluate the clinical characteristics of breast cancer among women above 70 years.
In this multi-central, retrospective and descriptive study, 2723 files of women with breast cancer referred to Mashhad Omid hospital and Reza Radiation oncology centre from 2001 to 2012 were evaluated. All the necessary data about age, family history, tumour pathology, clinical stage of tumour, hormone receptor status, Her2 protein status, type of surgery and type of adjuvant therapy ( radiotherapy, chemotherapy, hormone therapy ) were extracted from these files. Data was analysed with SPSS software (version 16). P The most common pathology was invasive ductal carcinoma (89.4%). 106 cases (65.8%) had positive estrogen receptor, 79 (9.8%) positive progesterone receptor and 89 (64.49%) negative Her2. Most patients (71.4%) had undergone modified radical mastectomy. The most common clinical stage was IIB (33.54%).
The most common type of breast cancer in women above 70 years is invasive ductal carcinoma and the most common stage of disease is IIB. Most patients are positive estrogen receptor and negative HER2. Therefore, it is recommended to pay more attention to their specific clinical characteristics in choosing their treatment approach.

Early diagnosis and appropriate treatment is required in esophageal cancer due to its invasive nature. The aim of this study was to evaluate early post-esophagectomy complications in patients with esophageal cancer who received neoadjuvant chemoradiotherapy (NACR). This randomized clinical trial was carried out between 2009 and 2011. Patients with lower-third esophageal cancer were randomly assigned to one of two groups. The first group consisted of 50 patients receiving standard chemoradiotherapy (Group A) and then undergoing surgery, and the second group consisted of 50 patients undergoing surgery only (Group B). Patients were evaluated with respect to age, gender, clinical symptoms, type of pathology, time of surgery, perioperative blood loss, and number of lymph nodes resected as well as early post-operative complicate including leakage at the anastomosis site, chylothorax and pulmonary complications, hospitalization period, and mortality rate within the first 30 days after surgery. The mean age of patients was 55 years. Seventy-two patients had squamous cell carcinoma (SCC) and 28 patients had adenocarcinoma (ACC). There was no significant difference between the two groups with respect to age, gender, time of surgery, complications including anastomotic leakage, chylothorax, pulmonary complications, cardiac complications, deep venous thrombosis (DVT), or mortality. However, there was a significant difference between the two groups regarding hospital stay, time of surgery, perioperative blood loss, and number of lymph nodes resected. The use of NACR did not increase early post-operative complications or mortality among patients with esophageal cancer.

Breast cancer is one of the most prevalent cancers that oncologists are faced with in their clinics. The varieties of clinical features of the disease result to very different scenarios in the processes of treatment decision making. While classic factors of stage, grade, age and hormone receptor status are still the criterion for choosing treatment, a very delicate list of other prognostic and predictive factors have been entered to this field over recent two decades. The evidence-based medicine rules to treat patients based on the best evidences that have been found by powered randomized clinical trials. Different panels and guidelines gathering these evidences try to help oncologists to find the best treatment methods through the variable and sometimes contradicting results. As it is always the main objective, increasing the survival rates in addition to the ideal aim of curing the disease is usually the target. Finding the best and the most practical chemotherapy regimen against breast cancer needs to notice the biology of this disease and its varieties along with each individual patient condition. It is clear that not all patients need the most complicated and expensive treatment.

Breast cancer is the most common malignancy in Iranian women. Several factors such as estrogen and progesterone receptors and P53 mutation can influence the prognosis in these patients. In the present study، the frequency of these prognostic factors and their correlation with patient age، tumor size and lymph nodes involvement were evaluated.

In this retrospective cohort study، over a 8-year period، 1022 cases of female breast cancer، referred to Mashhad Omid Hospital، entered for analysis.

Frequency of estrogen receptor (ER)، progesterone receptor (PR) and P53 mutation were 45. 5%، 43. 1%، and 18. 7%، respectively. There was a significant negative correlation between PR and lymph node involvement (P = 0. 006) and more axillary involvement was seen in PR negative patients. Metastasis had significant correlation with P53 mutation (P = 0. 005). Patients age significantly associated with ER، PR (P = 0. 00 and 0. 01 respectively)، such that the presence of ER،PR increased with age، but، P53 mutation had no significant correlation with age. There was a direct correlation between ER and PR (P = 0. 000) and also a reverse correlation between hormonal receptors and P53 (P = 0. 001).

P53 mutation was correlated with further metastasis and poor prognosis. Hormonal receptors could also predict axillary involvement. Evaluation of such biomarkers aided in estimation of disease prognosis.

Weight loss and malnutrition are common among cancer patients. These two factors highly affect their survival and quality of life during treatment. Since cancer is becoming increasingly common in the world and in order to provide better treatment measures, it is important to identify and prevent its side effects. The present study has been conducted in 2010 on a sample of cancer patients in the Oncology Center of Shahid Beheshti University of Medical Sciences to determine the prevalence rates and factors associated with malnutrition. The PG-SGA standard questionnaire was administered to 416 cancer patients to evaluate their nutrition status. The frequency of each malnutrition stage was determined. Correlations and ANOVA tests were used to analyze the relationship between factors predisposing to weight loss. The prevalence of malnutrition among the patients was 53.1%; out of which 29.1% had moderate and 24% had severe malnutrition. The most common factors inducing nutritional symptoms were depression and anorexia; 35% of the patients had >5% weight loss in the last 1 mouth. The average PG-SGA score was 10.11 with 49 being the highest score. 46.1 percent of the patients scored over 9 (requiring critical nutrient intervention). Malnutrition has a high correlation with weight loss, limitation of activities, nutritional symptoms, and the cancer stage, but it has a low correlation with treatment and the pathologic type. Malnutrition has a high prevalence in Iranian cancer patients and has a close relationship with mortality, morbidity and treatment-related problems and also quality of life, so periodical assessments by PG-SGA are necessary to detect malnutrition in patients and provide appropriate nutritional intervention.